Evidence map›Paper›PMID 36863535›Full record

ArticleThe Journal of infection2023

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.

Emily Shava, Alane Izu, Tendani Gaolathe, Adam Walker, Lucy Carty, Panayiotis Georgiou, Lesego Kuate, Coulson Kgathi, Tumalano Sekoto, Ngozana Seonyatseng and 18 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Emily ShavaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: emakunike@gmail.com.
Alane IzuSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Innovation/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: alane.izu@wits-vida.org.
Tendani GaolatheHarvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, United States; University of Botswana, Gaborone, Botswana. Electronic address: gaolathet@gmail.com.
Adam WalkerMedical Evidence, Vaccine and Immune Therapies, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK. Electronic address: adam.walker@astrazeneca.com.
Lucy CartyMedical and Payer Evidence Statistics, BioPharmaceuticals Medicine, AstraZeneca, Cambridge, UK. Electronic address: lucy.carty@astrazeneca.com.
Panayiotis GeorgiouLate Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: panos.georgiou@astrazeneca.com.
Lesego KuateMinistry of Health Botswana, Botswana. Electronic address: drkuate@gmail.com.
Coulson KgathiBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: ckgathi@bhp.org.bw.
Tumalano SekotoBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tsekoto@bhp.org.bw.
Ngozana SeonyatsengBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: nseonyatseng@bhp.org.bw.
Tuelo MogashoaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tmogashoa@bhp.org.bw.
Comfort MaphorisaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: cmaphorisa@bhp.org.bw.
Terence MohammedBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tmohammed@bhp.org.bw.
Tshenolo NtalabgweBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tntalabgwe@bhp.org.bw.
Tshepho T FrankBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tfrank@bhp.org.bw.
Boitumelo MatlhakuBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: bmatlhaku@bhp.org.bw.
Ame DiphokoBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: adiphoko@bhp.org.bw.
Thandie PhindelaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tphindela@bhp.org.bw.
Agripa KaundaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: akaunda@bhp.org.bw.
Poloko KgariBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: pkgari@bhp.org.bw.
Thomas KanyakulaBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: tkanyakula@bhp.org.bw.
Gape PalalaniBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: gpalalani@bhp.org.bw.
Isabella PhakediBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: phakedi@bhp.org.bw.
(Botswana AZD1222 study team)Botswana Harvard AIDS Institute Partnership, Botswana.
Sylvia TaylorInfection Evidence Strategy, Vaccine and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK. Electronic address: sylvia.taylor@astrazeneca.com.
Mompati MmalaneBotswana Harvard AIDS Institute Partnership, Botswana. Electronic address: mmmalane@bhp.org.bw.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Botswana; Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, United States. Electronic address: smoyo@bhp.org.bw.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Botswana; Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, United States. Electronic address: jmakhema@bhp.org.bw.

Funding

Viral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682k
FIC NIH HHS K43 TW012350
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChAdOx1 nCoV-19COVID-19Antibodies, ViralBotswanaCOVID-19 VaccinesHumansIncidenceVaccinationAntibodies, ViralChAdOx1 nCoV-19COVID-19 Vaccines

Identifiers

PMID36863535
PMCPMC9974206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.